High-quality biomarkers that detect emergent graft damage and/or rejection after solid-organ transplantation offer new opportunities to improve post-transplant monitoring, allow early therapeutic intervention and facilitate personalized patient management. Read more.
Cell-free DNA as a solid-organ transplant biomarker: technologies and approaches
